TopiVert to Present First-In-Human Data From Its Phase I Clinical Study With TOP1288 for the Treatment of Ulcerative Colitis at the Forthcoming 11th Congress of ECCO in Amsterdam
(firmenpresse) - LONDON, UNITED KINGDOM -- (Marketwired) -- 03/07/16 -- ("TopiVert" or the "Company"), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel locally-acting medicines for the treatment of chronic inflammatory diseases of the gastrointestinal tract and eye, announces that it will present Phase I study data results for TOP1288, its lead compound for the treatment of ulcerative colitis (UC), at the 11th Congress of ECCO (European Crohn's and Colitis Organisation) to be held on 16-19 March 2016 in Amsterdam, The Netherlands.
Data from its First-In-Human randomized double-blind placebo-controlled clinical trial of a novel narrow spectrum kinase inhibitor, will be presented on Friday 18 March 2016 in the "Clinical: therapy and observation" session along with a further four TopiVert posters. Senior members of the management and R&D teams will be available at the conference from 17 March to meet with interested parties.
Click on, or paste the following link into your web browser, to view the associated PDF document.
Steve Webber
Chief Scientific Officer
+44 (0)20 3763 9468
Nick Staples
Business Development
+44 (0)7818 075816
Mary-Jane Elliott / Ivar Milligan / Hendrik Thys
+44 (0)20 3709 5700
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 07.03.2016 - 07:00 Uhr
Sprache: Deutsch
News-ID 455462
Anzahl Zeichen: 0
contact information:
Town:
LONDON, UNITED KINGDOM
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 243 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TopiVert to Present First-In-Human Data From Its Phase I Clinical Study With TOP1288 for the Treatment of Ulcerative Colitis at the Forthcoming 11th Congress of ECCO in Amsterdam"
steht unter der journalistisch-redaktionellen Verantwortung von
TopiVert Pharma Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
